Chimeric antigen receptor T cell therapy for multiple myeloma

Mostrar otras versiones (1)

Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma. Now, many researchers are developing CAR T cells for multiple myeloma. CAR T cells t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Kana, Hosen, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547554/
https://www.ncbi.nlm.nih.gov/pubmed/31171941
http://dx.doi.org/10.1186/s41232-019-0100-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547554/
https://www.ncbi.nlm.nih.gov/pubmed/31171941
http://dx.doi.org/10.1186/s41232-019-0100-6

Ejemplares similares